Full Press Release Details
| FOR MORE INFORMATION: | Company Contact: |
| Jacqueline Lemke | |
| President & CEO | |
| Phone: 765.497.5829 | |
| jlemke@BASinc.com | |
| Agency Contact: | |
| Neil Berkman | |
| Berkman Associates | |
| Phone: 310.477.3118 | |
| info@berkmanassociates.com |
BASi Names Jeffrey Potrzebowski
James Bourdage VP Bioanalytical
LAFAYETTE, IN - June 12, 2014 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced the appointment of
Jeffrey Potrzebowski as Chief Financial Officer and James S. Bourdage, Ph.D., as Vice President Bioanalytical Operations.
& CEO Jacqueline Lemke said, "These appointments represent significant steps forward in our continuing program to build
a management team with the depth, experience and dedication to take BASi to the next level and achieve our goals for growth and
profitability. Each of these senior executives brings an impressive record of accomplishment to his new role at BASi: Jeff Potrzebowski
in financial management, reporting, planning and related public company CFO functions; and Jim Bourdage in the leadership and management
of large global laboratory operations in the pharmaceutical and biotech industries. We welcome Jeff and Jim to BASi, and look forward
to their contributions to our continued success."
Jeffrey Potrzebowski, CPA
Potrzebowski joins BASi after serving since 2006 in various positions of increasing responsibility with Oerlikon Drive Systems,
Lafayette, Indiana, most recently as Chief Financial Officer of this $800 million manufacturer of gear and drive solutions, where
he was responsible for the management and control of financial performance of the Operating Segment reporting to the Segment CEO.
Earlier, he was Senior Vice President and Chief Financial Officer of Remy International, Anderson, Indiana, a producer of electrical
automotive parts with sales in excess of $1.2 billion. Previously, Mr. Potrzebowski was Senior Vice President and Chief Financial
Officer of Great Lakes Chemical, Indianapolis, a $1.6 billion specialty chemical company, which he joined in 1993.
began his career with Price Waterhouse in Toledo. He received a BA in Accounting from Toledo University in 1975 and a CPA in 1976.
James S. Bourdage, Ph.D.
Bourdage was Executive Director Biopharmaceutical CMC Solutions at Covance Inc., Greenfield, Indiana, since 2011, where he was
responsible for the US Biotechnology CMC operation of this $2.4 billion drug development services organization. Earlier, he was
Senior Director, Bioanalytical Sciences, at Pharmathene, Inc., Annapolis, Maryland, a biodefense company with more than $300 million
in government contracts. From 2003 to 2009, Dr. Bourdage was Global Research Advisor and Team Leader, Laboratory for Experimental
Medicine at Eli Lilly Co., Indianapolis, where his responsibilities included oversight of biotherapeutic immunogenicity and biomarker
assay development to support global clinical trials. Previously, he was Senior Research Scientist, Drug Absorption and Transport
at Pharmacia (Upjohn), Kalamazoo, Michigan, where he received the Upjohn Corporate Special Recognition Award in 1992 and the Quality
Control Achievement Award in 1993.
received a Ph.D. in Immunochemistry from the University of Illinois in 1979. He is a member of the American Society of Clinical
Pathologists and the American Association of Pharmaceutical Scientists, and is the author of numerous scientific papers.
About Bioanalytical Systems,
a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug
development companies and medical research organizations. The company focuses on developing innovative services and products that
increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.
This release contains forward-looking
statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes
in the market and demand for our products and services, the development, marketing and sales of products and services, changes
in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings
with the Securities and Exchange Commission.